Diabetic nephropathy
- 13 July 2002
- Vol. 325 (7355) , 59-60
- https://doi.org/10.1136/bmj.325.7355.59
Abstract
Footnotes Competing interests The author was an investigator in the irbesartan diabetic nephropathy trial (IDNT) and the MARVAL trial (valsartan). He has attended meetings and lectured on diabetic nephropathy, sometimes with the support of various pharmaceutical companies.Keywords
This publication has 9 references indexed in Scilit:
- Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- Population‐based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetesDiabetic Medicine, 2001
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) studyBMJ, 2000
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.2000
- Prediction of albumin excretion rate from albumin-to-creatinine ratio.Diabetes Care, 1999
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993